Acumen Diagnostics, a 51%-owned subsidiary of Q&M Dental Group and 49%-owned by Aoxin Q&M Dental Group, says it has been granted a license by the Ministry of Health (MOH) to provide offsite Covid-19 polymerase chain reaction (PCR) swab services and serology sample collection.
Acumen Diagnostics will roll out its testing services via Q&M Dental’s clinics, as well as its headquarters at The Gemini at 41 Science Park.
With the onset of the Omicron variant and the opening of the vaccinated travel lane (VTL) arrangements, the company will increase its Covid-19 PCR testing services to include 10 Q&M Dental clinics by Dec 31.
More sites will be added in the next few months with the potential capacity to activate 100 sites islandwide.
PCR test results will be made available in as early as four hours. Doorstep PCR testing services are also available.
“Vaccination coupled with a robust testing regime remains the best strategy to tackle the virus enabling a safe and more sustainable reopening of the economy,” says Dr Ong Siew Hua, CEO and chief scientist of Acumen Diagnostics. Ong is also the executive director of Aoxin Q&M Dental.
See also: BioNTech beats estimates as vaccine maker pursues more diseases
“PCR tests remain the gold standard for accurately detecting Covid-19 cases and with the potential higher transmissibility of new variants such as Omicron, testing needs to be deployed quickly and provide highly accurate results to control the spread of the virus,” she adds.
Shares in Q&M and Aoxin Q&M closed at 59 cents and 23.5 cents respectively on Dec 15.
